Dec 22 (Reuters) - AlloVir said on Friday it will discontinue three late-stage studies testing its experimental antiviral cell therapy after an independent safety board said the studies were unlikely to meet their main goals. (Reporting by Mariam Sunny in Bengaluru; Editing by Devika Syamnath)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.774 USD | -1.46% | -3.86% | +14.05% |
03-20 | North American Morning Briefing : Markets on Hold -2- | DJ |
03-15 | AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.05% | 87.71M | |
+5.04% | 109B | |
+11.00% | 105B | |
-0.38% | 22.25B | |
-12.00% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.03% | 16.85B | |
+3.57% | 13.76B | |
+36.18% | 12.46B |
- Stock Market
- Equities
- ALVR Stock
- News AlloVir, Inc.
- AlloVir scraps late-stage studies testing antiviral cell therapy